

# Puma Biotechnology

## Earnings Call

### Commercial Update




February 20, 2020

**nerlynx**<sup>®</sup>  
(neratinib) tablets


# Forward-Looking Safe Harbor Statement

*This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward-looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward-looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These risks and uncertainties are identified in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including, once filed, Puma’s Annual Report on Form 10-K for the year ended December 31, 2019. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.*

# Puma's Pharmacy and Distributor Network




# \$58.7 Million Net Revenue in Q4 2019



# ~29% of Patients in Q4 Started NERLYNX at a Reduced Dose


## PERCENT OF PATIENT STARTS AT REDUCED DOSE



- *Reduced Dose defined as fewer than 6 pills per day; On-Label Patients Only*

# Bottles Sold By Quarter

BOTTLES SOLD BY QUARTER (SP+SD)



• SP = Specialty Pharmacy Network, SD = Specialty Distributor Network; Bottles defined as 180 Pills



# Rest of World Partnerships – Timelines

| Region                         | Partner   | Expected Regulatory Approval  |
|--------------------------------|---|---|
| Australia / SE Asia            |  <b>Specialised Therapeutics</b>                                   | <ul style="list-style-type: none"> <li>• <b>March 2019 – Approved in Australia</b></li> <li>• <b>December 2019 -- Approved in Singapore</b></li> </ul>  |
| Israel                         |  <b>MEDISON</b><br><small>Delivering Innovative Healthcare</small> | <ul style="list-style-type: none"> <li>• <b>Q1 2020</b></li> </ul>  |
| Canada                         |  <b>Knight</b>   | <ul style="list-style-type: none"> <li>• <b>July 2019 – Approved</b></li> </ul>   |
| Greater China                  |  <b>CANbridge</b><br><small>北海康成</small>                           | <ul style="list-style-type: none"> <li>• <b>November 2019 – Approved in Hong Kong</b></li> <li>• <b>1H 2020 – China</b></li> <li>• <b>1H 2020 – Taiwan</b></li> </ul>   |
| Latin America<br>South America |  <b>PINT PHARMA</b>  | <ul style="list-style-type: none"> <li>• <b>September 2019 – Approved in Argentina</b></li> <li>• <b>1H 2020 – Chile, Peru</b></li> <li>• <b>2H 2020 – Mexico</b></li> <li>• <b>2H 2020 – Colombia, Brazil, Ecuador</b></li> </ul>                                |
| Europe                         |  <b>Pierre Fabre</b>   | <p><b>Launch Timelines</b></p> <ul style="list-style-type: none"> <li>• <b>Q4 2019 – Germany-Launched</b></li> <li>• <b>Q4 2019 – United Kingdom-Launched</b></li> <li>• <b>Q4 2019 – Austria-Launched</b></li> <li>• <b>2020-2022– Rest of Europe</b></li> </ul> |

# Puma Biotechnology

## Earnings Call

### Commercial Update



February 20, 2020

**nerlynx**<sup>®</sup>  
(neratinib) tablets